Interferon-α treatment of patients with hepatitis C: The role of a comprehensive risk-benefit assessment (multiple letters)

CNS Drugs

Volumn 19, Issue 8, 2005, Pages 719-721

  Rifai, Muhamad Aly ^a,b,c   Loftis, Jennifer M ^b,c,d   Hauser, Peter ^b,c,d   Raison, Charles L ^e   Demetrashvili, Marina ^e   Capuron, Lucile ^e   Miller, Andrew H ^e  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Northwest Hepatitis C Resource Center   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RECOMBINANT INTERFERON;

AGRANULOCYTOSIS; ANEMIA; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; MENTAL DISEASE; MORBIDITY; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; SUICIDE; VIRUS INFECTION; RISK ASSESSMENT;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; RISK ASSESSMENT;

EID: 24144458304     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200519080-00009     Document Type: Letter

References (9)

1. 1. CL Raison M Demetrashvili L Capuron 2005 Neuropsychiatric adverse effects of interferon-alpha: recognition and management CNS Drugs 19 2 105 23 15697325 10.2165/00023210-200519020-00002 1:CAS:528:DC%2BD2MXislCqs7o%3D Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19(2): 105–23
2. 2. SP Yovtcheva MA Rifai JK Moles 2001 Psychiatric comorbidity among hepatitis C positive patients Psychosomatics 42 5 411 5 11739908 10.1176/appi.psy.42.5.411 1:STN:280:DC%2BD3Mnpt1ylsQ%3D%3D Yovtcheva SP, Rifai MA, Moles JK, et al. Psychiatric comorbidity among hepatitis C positive patients. Psychosomatics 2001; 42(5): 411–5
3. 3. MA Rifai JK Moles BJ Linden Van Der 2003 The prevalence of psychiatrie disorders in patients with chronic hepatitis C Psychosomatics 44 2 142 3 Rifai MA, Moles JK, Van Der Linden BJ. The prevalence of psychiatrie disorders in patients with chronic hepatitis C. Psychosomatics 2003; 44(2): 142–3
4. 4. HB el-Serag M Kunik P Richardson 2002 Psychiatrie disorders among veterans with hepatitis C infection Gastroenterology 123 2 476 82 12145801 10.1053/gast.2002.34750 el-Serag HB, Kunik M, Richardson P, et al. Psychiatrie disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123(2): 476–82
5. 5. SD Rosenberg JW Swanson GL Wolford 2003 Blood-borne infections and persons with mental illness: the five-site health and risk study of blood-borne infections among persons with severe mental illness Psychiatric Services 54 6 827 35 12773596 10.1176/appi.ps.54.6.827 Rosenberg SD, Swanson JW, Wolford GL, et al. Blood-borne infections and persons with mental illness: the five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatric Services 2003; 54(6): 827–35
6. 6. MA Rifai DL Rosestein 2005 Interferon treatment of hepatitis C patients with psychiatric disorders: evidence-based, risk-benefit assessment Psychosomatics 46 2 165 6 Rifai MA and Rosestein DL. Interferon treatment of hepatitis C patients with psychiatric disorders: evidence-based, risk-benefit assessment. Psychosomatics 2005; 46(2): 165–6
7. 7. MA Rifai B Bozorg DL Rosenstein 2004 Interferon for hepatitis C patients with psychiatric disorders Am J Psychiatry 161 12 2331 2 15569919 10.1176/appi.ajp.161.12.2331 Rifai MA, Bozorg B, Rosenstein DL. Interferon for hepatitis C patients with psychiatric disorders. Am J Psychiatry 2004; 161(12): 2331–2
8. 8. R Chou EC Clark M Helfand 2004 Screening for hepatitis C virus infection: a review of the evidence for the U.S Preventive Services Task Force. Ann Intern Med 140 6 465 79 Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004; 140(6): 465–79
9. 9. D Strader T Wright DL Thomas 2004 Diagnosis, management, and treatment of hepatitis C Hepatology 39 4 1147 71 15057920 10.1002/hep.20119 Strader D, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39(4): 1147–71